Parotid Gland Tumors: Evaluation, Surgical Options and Facial Nerve Preservation

The parotid gland is the largest salivary gland of the head and neck — located in front of the ear, lateral to the mandible, overlying the masseter muscle. Weighs about 25-30 g. Produces 25% of saliva; primarily serous saliva during chewing.

Anatomically the most critical feature is that the facial nerve (CN VII) passes through the parotid. After exiting the stylomastoid foramen, the nerve enters the gland and divides into 5 branches: temporal, zygomatic, buccal, mandibular and cervical. These innervate the facial expression muscles.

This anatomy makes parotid surgery especially challenging: removing the tumor while preserving the facial nerve. About 80% of tumors are in the superficial lobe (lateral to the nerve); 20% in the deep lobe (medial). The nerve serves as the "surgical plane" separating the gland into superficial and deep lobes.

Other important structures: parotid (Stensen's) duct connecting the gland to the oral cavity, external carotid artery and branches (passing through), retromandibular vein, auriculotemporal nerve (can cause Frey's syndrome complication). We expand on the clinical framework in our head and neck cancer surgery programme.

Parotid tumors are classified conceptually into two categories: benign (~80%) and malignant (~20%). Among benign:

Pleomorphic adenoma: 60-70% of benign tumors. Presents as a slow-growing, painless, mobile mass. More common in women aged 30-50. Histologically has epithelial + myxoid components. Malignant transformation risk 3-10% — increases with 10+ years follow-up.

Warthin's tumor (papillary cystadenoma lymphomatosum): 5-15% of benign tumors. Markedly more common in male smokers. Bilateral in 10-15%. Slow-growing, painless. Lower transformation risk than pleomorphic adenoma.

Other benign: basal cell adenoma, oncocytoma, canalicular adenoma, lipoma. All slow-growing, localised lesions.

Malignant tumors: mucoepidermoid carcinoma (most common malignancy, 30%) — low-, intermediate-, high-grade. Acinic cell carcinoma (17%) — low-grade but slow spread. Adenoid cystic carcinoma (10%) — perineural invasion tendency (poor prognosis). Adenocarcinoma NOS, salivary duct carcinoma, carcinoma ex pleomorphic adenoma (transformation from pleomorphic), squamous cell, undifferentiated carcinoma.

Evaluation of a patient with a parotid mass is systematic. Step 1: detailed history and physical examination — mass duration, growth rate, pain, facial weakness, palpable cervical nodes, skin fixation.

Ultrasound: first-line imaging. Assesses location (superficial/deep lobe), size, margins (regular/irregular), internal echogenicity, vascularity. Benign tumors are usually well-circumscribed; malignant tumors are irregular, infiltrative.

Fine-needle aspiration biopsy (FNA): performed under ultrasound guidance, outpatient. Sensitivity 85%+ for benign and 75-90% for malignant. Milan System for Reporting (analogous to Bethesda) is used: non-diagnostic, non-neoplastic, atypia, benign neoplasm, suspicious for neoplasm, suspicious for malignancy, malignant. FNA result drives the surgical plan.

MRI: gold standard for surgical planning. Shows tumor location (lobe), deep extension, proximity to facial nerve, parapharyngeal extension, perineural invasion, malignant features (capsule invasion, infiltration). T1, T2 and contrast sequences are combined.

CT: when bony invasion is suspected or MRI is contraindicated. PET-CT: in malignant cases for staging + distant metastasis screening.

The core principle of parotid surgery: remove the tumor "outside the capsule" — taking the tumor with surrounding healthy gland tissue. Simple tumor enucleation is not done because pleomorphic adenoma recurrence after enucleation reaches 20-45% (microscopic spread).

Superficial parotidectomy: the most common operation. After identifying the facial nerve, the superficial lobe with the tumor is removed. Standard for benign superficial-lobe tumors. Takes 1.5-2 hours, hospital stay 1-2 days.

Extracapsular dissection (ECD): minimally invasive approach for selected small superficial benign tumors. Only the tumor and 2-3 mm of healthy tissue are removed. In modern series, recurrence is similar to superficial parotidectomy (2-5%). Lower risk of facial nerve dysfunction.

Deep-lobe parotidectomy: for deep-lobe tumors, the deep lobe is removed with facial nerve preservation (usually superficial parotidectomy first, then nerve retracted inferiorly to remove the deep lobe).

Total parotidectomy: entire gland (superficial + deep) removed. For malignant tumors, large deep-lobe tumors, intraparotid lymph node metastasis, parapharyngeal extension.

Total parotidectomy + facial nerve sacrifice: rarely done if cancer invades the facial nerve — nerve sacrificed + grafting (typically greater auricular or sural nerve) for reconstruction.

Neck dissection: added in malignant cases as Level II-III selective (cN0) or extended (cN+). More detail: head and neck cancer symptoms.

Facial nerve preservation is central to parotid surgery success. Nerve injury leaves the patient with permanent facial paralysis — functional, aesthetic and psychological impacts are major.

Nerve identification: the type 1 main trunk (at stylomastoid foramen exit) is found using anatomic landmarks — tragal pointer, retromandibular vein, posterior belly of digastric, mastoid tip, styloid process. In superficial parotidectomy the surgeon must first expose the nerve.

Intraoperative nerve monitoring (IONM): standard in modern surgery. Stimulating the nerve produces an EMG response on the Nerve Integrity Monitor (NIM). Lets the surgeon track nerve proximity continuously. Studies show IONM reduces transient nerve dysfunction (about 17% → 8%).

Postoperative transient facial nerve dysfunction: occurs in 20-30% — mostly self-resolves in 3-6 months. The lower branches (marginal mandibular) are most sensitive. Permanent dysfunction: 1-3% in superficial parotidectomy, 3-5% in total parotidectomy, higher in malignant surgery.

If nerve injury occurs: early physiotherapy, eye protection (artificial tears + nocturnal protection for corneal dryness), early neurosurgical consultation (nerve graft or hypoglossal-facial anastomosis). Later: muscle transfer or permanent aesthetic correction.

Frey's syndrome (auriculotemporal syndrome): a late parotidectomy complication (post-op 6-12 months). Cheek sweating and flushing when seeing/smelling food or chewing. Cause: severed auriculotemporal nerve fibres reinnervating the wrong target — sweat glands instead of salivary.

Frequency: subjective post-op 30-90%, but severe (socially troubling) 10-15%. Diagnosis: Minor's test (iodine-starch method). Treatment: mild cases none; moderate-severe cases botulinum toxin (Botox) injection — 6-12 month effect, may need repeats. Surgery (SMAS flap, ADM interposition) is sometimes prophylactic.

Other complications: sialocele/salivary fistula (post-op saliva collection — mostly conservative, anticholinergics help), earlobe numbness (auriculotemporal nerve transection — permanent), wound infection (2-3%), haematoma (1-2%), cosmetic concavity (especially after total parotidectomy — reconstruction with SMAS flap or fat graft).

Scar: the standard Blair incision (S-shaped from in front of the ear to retromandibular area) hides at the hairline; fades in 6-12 months. Modified facelift incision is more cosmetic — preferred especially in younger patients.

Adjuvant therapy after surgery may be needed in malignant parotid tumors. The decision is based on pathology — tumor type, grade, size, margin status, perineural invasion, nodal status (LN+), extranodal extension.

Adjuvant radiotherapy indications: high-grade tumor, positive/close margins, T3-T4 stage, nodal positivity (especially with extranodal extension), perineural invasion, lymphovascular invasion. Typical dose 60-66 Gy over 6-7 weeks.

Chemotherapy: does not replace radiotherapy in parotid cancers; only in very advanced cases or as chemoradiotherapy (CRT). Limited effect on systemic disease.

Follow-up protocol: every 3 months in the first 2 years, every 6 months in years 3-5, yearly after 5. Physical exam + neck ultrasound, MRI if indicated. Annual chest CT for distant metastasis. PET-CT in suspicious cases.

Prognosis: 5-year survival varies widely by type and stage — 90%+ for low-grade mucoepidermoid carcinoma, 50-70% for high-grade adenoid cystic, 30-50% for salivary duct carcinoma. Early diagnosis matters; small tumors have far better prognosis than large. We share patient experiences on our multidisciplinary tumour board.